← Leaderboards
Nisha Acharya
University Of California, San Francisco
$16,289,853
Attributed
$16,515,353
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,515,353 · 5
By mechanism
UG1$6,485,536 · 1
U10$4,565,745 · 1
R01$3,883,069 · 1
K23$1,130,003 · 1
R21$451,000 · 1
Top collaborators
- Thuy A Doan2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Li Li$40,835
- John Daniel Kelly$1,673,513
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationMorbidity - Disease RateAffectLeadBlindnessChronicIncidenceSafetyClinical TrialsUveitisRecurrenceCaliforniaUniversitiesEtiologyInfectionMasksPharmaceutical PreparationsRandomizedInflammatoryAdverse EventImmuneSteroidsQuality Of LifeMediating
Grant awards (30)
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$606,382
R01 · FY2025 · EY · contact PI
Programmable Phage Display Peptidomes to Characterize Uveitis$205,000
R21 · FY2025 · EY
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$623,881
R01 · FY2024 · EY · contact PI
Programmable Phage Display Peptidomes to Characterize Uveitis$246,000
R21 · FY2024 · EY
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial$1,229,055
UG1 · FY2023 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$624,493
R01 · FY2023 · EY · contact PI
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial$1,228,271
UG1 · FY2022 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$384,363
R01 · FY2022 · EY · contact PI
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Trial (ADJUST) - Diversity Supplement$72,643
UG1 · FY2022 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$23,292
R01 · FY2022 · EY · contact PI
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial$1,203,374
UG1 · FY2021 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$384,362
R01 · FY2021 · EY · contact PI
Diversity Supplement: The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$47,546
R01 · FY2021 · EY · contact PI
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial$1,311,890
UG1 · FY2020 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$396,250
R01 · FY2020 · EY · contact PI
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial$1,440,303
UG1 · FY2019 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$396,250
R01 · FY2019 · EY · contact PI
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus$396,250
R01 · FY2018 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$789,850
U10 · FY2016 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$1,122,427
U10 · FY2015 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$909,873
U10 · FY2014 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$244,262
U10 · FY2014 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$661,368
U10 · FY2013 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$250,000
U10 · FY2013 · EY · contact PI
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial$587,965
U10 · FY2012 · EY · contact PI
Predicting and Improving Clinical Outcomes for Bacterial Keratitis$239,496
K23 · FY2011 · EY · contact PI
Predicting and Improving Clinical Outcomes for Bacterial Keratitis$239,496
K23 · FY2010 · EY · contact PI
Predicting and Improving Clinical Outcomes for Bacterial Keratitis$239,496
K23 · FY2009 · EY · contact PI
Predicting and Improving Clinical Outcomes for Bacterial Keratitis$208,411
K23 · FY2008 · EY · contact PI
Predicting and Improving Clinical Outcomes for Bacterial Keratitis$203,104
K23 · FY2007 · EY · contact PI